Latest posts
-
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
WARREN, N.J., Nov. 29, 2023 — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the “NYSE Regulation”) has determined to immediately suspend trading in the Company’s common
-
EASY ENERGY SYSTEMS TO EXHIBIT AT ORGANIC GROWERS SUMMIT IN MONTEREY, CA
Mankato, Minnesota, November 21, 2023 – Digital Utilities Ventures, Inc. (OTC: DUTV), announces that its planned future affiliate, Easy Energy Systems, Inc., will be exhibiting at the Organic Growers Show in Monterey on November 29-30. The summit provides growers firsthand knowledge and information in a variety of areas ranging from Agtech to food safety to
-
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results
Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski,
-
Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug
“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,”
-
Oncocyte Reports Third Quarter 2023 Financial Results
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights Josh Riggs, CEO
-
Blue Water Petroleum Corp (BWPC) To Showcase Hydrogen Fuel Processing Technology
CHEYENNE, WY, November 8, 2023 – Blue Water Petroleum Corp’s (OTC PINK: BWPC), wholly owned subsidiary Attimar SA, has developed cutting-edge hydrogen processing technologies which produce sustainable and ecologically viable fuels. These new H2 based fuels represent significant steps towards reducing the global dependency on fossil fuels, as they are designed to completely replace methane
-
Digital Utilities Ventures, Inc. (OTC: DUTV) Subsidiary and Nano Gas™ Environmental Agree to Exclusive Global License For Nanobubble Technology in Agriculture and Related Markets
Mankato, Minnesota, November 8, 2023 – Digital Utilities Ventures, Inc. (OTC: DUTV) announces that Nano Gas Environmental (Nano Gas™) has exclusively licensed the Nano Gas Technologies patents and intellectual property to the public company Digital Utilities Ventures, Inc. future subsidiary of Easy Modular Manufacturing (EMM) for use in the Global Agricultural and related markets (other
-
BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
POMPANO BEACH, FLORIDA, November 6, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a
-
BioStem Technologies Closes Oversubscribed $2M Private Placement
POMPANO BEACH, FLORIDA, November 3, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each,
-
Oncocyte to Announce Third Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m.